FL
Florida House Bill H7087

Florida 2024 Regular Session

Florida House Bill H7087 Compare Versions

Only one version of the bill is available at this time.
OldNewDifferences
11
22
33 HB 7087 2024
44
55
66
77 CODING: Words stricken are deletions; words underlined are additions.
88 hb7087-00
99 Page 1 of 9
1010 F L O R I D A H O U S E O F R E P R E S E N T A T I V E S
1111
1212
1313
1414 A bill to be entitled 1
1515 An act relating to cancer funding; amending s. 2
1616 381.915, F.S.; revising the purpose of the Casey 3
1717 DeSantis Cancer Research Program; revising duties of 4
1818 the Department of Health under the program; creating 5
1919 the Cancer Connect Collaborative within the department 6
2020 for a specified purpose; authorizing the collaborative 7
2121 to make certain recommendations on state policy 8
2222 relating to cancer research or treatment; providing 9
2323 for membership and meetings of the collaborative; 10
2424 requiring the collaborative to develop a long -range 11
2525 comprehensive plan for the program; requiring the 12
2626 collaborative to solicit input from certain 13
2727 stakeholders in the development of the plan; requiring 14
2828 the collaborative to submit the plan to the Governor 15
2929 and the Legislature by a specified date; specifying 16
3030 required components of the plan; requiring the 17
3131 department to provide administrative support and staff 18
3232 to the collaborative; requiring the collaborative to 19
3333 administer the Cancer Innovation Fund; requiring the 20
3434 collaborative to review grant applications and m ake 21
3535 recommendations to the department for awarding grants 22
3636 upon the appropriation of funds to the fund; requiring 23
3737 the department to make the final grant allocation 24
3838 award; requiring the collaborative to prioritize 25
3939
4040 HB 7087 2024
4141
4242
4343
4444 CODING: Words stricken are deletions; words underlined are additions.
4545 hb7087-00
4646 Page 2 of 9
4747 F L O R I D A H O U S E O F R E P R E S E N T A T I V E S
4848
4949
5050
5151 certain applications for grant funding; revi sing the 26
5252 frequency with which the department, in conjunction 27
5353 with participating cancer centers, must submit a 28
5454 specified report to the Cancer Control and Research 29
5555 Advisory Council and the collaborative; requiring the 30
5656 department to submit the report, and any equivalent 31
5757 independent reports, to the Governor and the 32
5858 Legislature by a specified date each year; revising 33
5959 requirements of such reports; beginning on a specified 34
6060 date, requiring that each allocation agreement issued 35
6161 by the department relating to certain cancer center 36
6262 payments include specified elements; providing an 37
6363 effective date. 38
6464 39
6565 Be It Enacted by the Legislature of the State of Florida: 40
6666 41
6767 Section 1. Subsections (8), (9), and (10) of section 42
6868 381.915, Florida Statutes, are renumbered as subsection s (10), 43
6969 (12), and (13), respectively, subsection (2) and present 44
7070 subsection (8) are amended, and new subsections (8) and (9) and 45
7171 subsection (11) are added to that section, to read: 46
7272 381.915 Casey DeSantis Cancer Research Program. — 47
7373 (2) The Casey DeSantis Cancer Research Program is 48
7474 established to enhance the quality and competitiveness of cancer 49
7575 care in this state, further a statewide biomedical research 50
7676
7777 HB 7087 2024
7878
7979
8080
8181 CODING: Words stricken are deletions; words underlined are additions.
8282 hb7087-00
8383 Page 3 of 9
8484 F L O R I D A H O U S E O F R E P R E S E N T A T I V E S
8585
8686
8787
8888 strategy directly responsive to the health needs of Florida's 51
8989 citizens, and capitalize on the potential educational 52
9090 opportunities available to its students , and promote the 53
9191 provision of high-quality, innovative health care for persons 54
9292 undergoing cancer treatment in this state . The department shall : 55
9393 (a) Make payments to cancer centers recognized by the 56
9494 National Cancer Institute (NCI) at the National Institutes of 57
9595 Health as NCI-designated cancer centers or NCI -designated 58
9696 comprehensive cancer centers, and cancer centers working toward 59
9797 achieving NCI designation. The department shall distribute funds 60
9898 to participating cancer centers on a quarterly basis during each 61
9999 fiscal year for which an appropriation is made. 62
100100 (b) Make cancer innovation grant funding available through 63
101101 the Cancer Innovation Fund administered by the Cancer Connect 64
102102 Collaborative under subsection (9) to health care providers and 65
103103 facilities that demonstrate excellence in patient -centered 66
104104 cancer treatment or research. 67
105105 (8) The Cancer Connect Collaborative, a council as defined 68
106106 in s. 20.03, is created within the department to advise the 69
107107 department and the Legislature on developing a holistic approach 70
108108 to the state's efforts to fund cancer research, cancer 71
109109 facilities, and treatments for cancer patients. The 72
110110 collaborative may make recommendations on proposed legislation, 73
111111 proposed rules, best practices, data collection and reporting, 74
112112 issuance of grant funds, and other proposals for state policy 75
113113
114114 HB 7087 2024
115115
116116
117117
118118 CODING: Words stricken are deletions; words underlined are additions.
119119 hb7087-00
120120 Page 4 of 9
121121 F L O R I D A H O U S E O F R E P R E S E N T A T I V E S
122122
123123
124124
125125 relating to cancer research or treatment. 76
126126 (a) The Surgeon General shall serve as an ex officio, 77
127127 nonvoting member and shall serve as the chair. 78
128128 (b) The collaborative shall be composed of the following 79
129129 voting members, to be appointed by September 1, 2024: 80
130130 1. Two members appointed by the Governor, one member 81
131131 appointed by the President of the Senate, and one member 82
132132 appointed by the Speaker of the House of Represen tatives, based 83
133133 on the criteria of this subparagraph. The appointing officers 84
134134 shall make their appointments prioritizing members who have 85
135135 experience or expertise in the following: 86
136136 a. The practice of a health care profession specializing 87
137137 in oncology clinical care or research; 88
138138 b. The development of preventive and therapeutic 89
139139 treatments to control cancer; 90
140140 c. The development of innovative research into the causes 91
141141 of cancer, the development of effective treatments for persons 92
142142 with cancer, or cures for cance r; or 93
143143 d. Management-level experience with a cancer center 94
144144 licensed under chapter 395. 95
145145 2. One member who is a resident of this state who can 96
146146 represent the interests of cancer patients in this state, 97
147147 appointed by the Governor. 98
148148 (c) The terms of appointees under paragraph (b) shall be 99
149149 for 2 years unless otherwise specified. However, to achieve 100
150150
151151 HB 7087 2024
152152
153153
154154
155155 CODING: Words stricken are deletions; words underlined are additions.
156156 hb7087-00
157157 Page 5 of 9
158158 F L O R I D A H O U S E O F R E P R E S E N T A T I V E S
159159
160160
161161
162162 staggered terms, the initial appointees under that paragraph 101
163163 shall serve 3 years for their first term. These appointees may 102
164164 be reappointed for no more than four consecutive terms. 103
165165 (d) Any vacancy occurring on the collaborative must be 104
166166 filled in the same manner as the original appointment. Any 105
167167 member who is appointed to fill a vacancy occurring because of 106
168168 death, resignation, or ineligibilit y for membership shall serve 107
169169 only for the unexpired term of the member's predecessor. 108
170170 (e) Members whose terms have expired may continue to serve 109
171171 until replaced or reappointed, but for no more than 6 months 110
172172 after the expiration of their terms. 111
173173 (f) Members shall serve without compensation but are 112
174174 entitled to reimbursement for per diem and travel expenses 113
175175 pursuant to s. 112.061. 114
176176 (g) The collaborative shall meet as necessary, but at 115
177177 least quarterly, at the call of the chair. A majority of the 116
178178 members of the collaborative constitutes a quorum, and a meeting 117
179179 may not be held with less than a quorum present. In order to 118
180180 establish a quorum, the collaborative may conduct its meetings 119
181181 through teleconference or other electronic means. The 120
182182 affirmative vote of a maj ority of the members of the 121
183183 collaborative present is necessary for any official action by 122
184184 the collaborative. 123
185185 (h) The collaborative shall develop a long -range 124
186186 comprehensive plan for the Casey DeSantis Cancer Research 125
187187
188188 HB 7087 2024
189189
190190
191191
192192 CODING: Words stricken are deletions; words underlined are additions.
193193 hb7087-00
194194 Page 6 of 9
195195 F L O R I D A H O U S E O F R E P R E S E N T A T I V E S
196196
197197
198198
199199 Program. In the development of the pla n, the collaborative must 126
200200 solicit input from cancer centers, research institutions, 127
201201 biomedical education institutions, hospitals, and medical 128
202202 providers. The collaborative shall submit the plan to the 129
203203 Governor, the President of the Senate, and the Speaker o f the 130
204204 House of Representatives no later than December 1, 2024. The 131
205205 plan must include, but need not be limited to, all of the 132
206206 following components: 133
207207 1. Expansion of grant fund opportunities to include a 134
208208 broader pool of Florida -based cancer centers, researc h 135
209209 institutions, biomedical education institutions, hospitals, and 136
210210 medical providers to receive funding through the Cancer 137
211211 Innovation Fund. 138
212212 2. An evaluation to determine metrics that focus on 139
213213 patient outcomes, quality of care, and efficacy of treatment. 140
214214 3. A compilation of best practices relating to cancer 141
215215 research or treatment. 142
216216 (i) The department shall provide reasonable and necessary 143
217217 support staff and materials to assist the collaborative in the 144
218218 performance of its duties. 145
219219 (9) The collaborative shal l administer the Cancer 146
220220 Innovation Fund. During any fiscal year for which funds are 147
221221 appropriated to the fund, the collaborative shall review all 148
222222 submitted grant applications and make recommendations to the 149
223223 department for awarding grants to support innovati ve cancer 150
224224
225225 HB 7087 2024
226226
227227
228228
229229 CODING: Words stricken are deletions; words underlined are additions.
230230 hb7087-00
231231 Page 7 of 9
232232 F L O R I D A H O U S E O F R E P R E S E N T A T I V E S
233233
234234
235235
236236 research and treatment models, including emerging research and 151
237237 treatment trends and promising treatments that may serve as 152
238238 catalysts for further research and treatments. The department 153
239239 shall make the final grant allocation awards. The collaborati ve 154
240240 shall give priority to applications seeking to expand the reach 155
241241 of innovative cancer treatment models into underserved areas of 156
242242 this state. 157
243243 (10)(8) Beginning July 1, 2025 2017, and each year every 3 158
244244 years thereafter, the department, in conjunction wit h 159
245245 participating cancer centers, shall submit a report to the 160
246246 Cancer Control and Research Advisory Council and the 161
247247 collaborative on specific metrics relating to cancer mortality 162
248248 and external funding for cancer -related research in this the 163
249249 state. If a cancer center does not endorse this report or 164
250250 produce an equivalent independent report, the cancer center is 165
251251 ineligible to receive shall be suspended from the program 166
252252 funding for 1 year. The department must submit this annual 167
253253 report, and any equivalent independe nt reports, to the Governor, 168
254254 the President of the Senate, and the Speaker of the House of 169
255255 Representatives no later than September 15 of each year the 170
256256 report or reports are submitted by the department. The report 171
257257 must include: 172
258258 (a) An analysis of trending age-adjusted cancer mortality 173
259259 rates in the state, which must include, at a minimum, overall 174
260260 age-adjusted mortality rates for cancer statewide and age -175
261261
262262 HB 7087 2024
263263
264264
265265
266266 CODING: Words stricken are deletions; words underlined are additions.
267267 hb7087-00
268268 Page 8 of 9
269269 F L O R I D A H O U S E O F R E P R E S E N T A T I V E S
270270
271271
272272
273273 adjusted mortality rates by age group, geographic region, and 176
274274 type of cancer, which must include, at a min imum: 177
275275 1. Lung cancer. 178
276276 2. Pancreatic cancer. 179
277277 3. Sarcoma. 180
278278 4. Melanoma. 181
279279 5. Leukemia and myelodysplastic syndromes. 182
280280 6. Brain cancer. 183
281281 7. Breast cancer. 184
282282 (b) Identification of trends in overall federal funding, 185
283283 broken down by institutional source, for cancer-related research 186
284284 in the state. 187
285285 (c) A list and narrative description of collaborative 188
286286 grants and interinstitutional collaboration among participating 189
287287 cancer centers, which may include grants received by 190
288288 participating cancer centers in collabor ation, a comparison of 191
289289 such collaborative grants in proportion to the grant totals for 192
290290 each cancer center, a catalog of retreats and progress seed 193
291291 grants using state funds, and targets for collaboration in the 194
292292 future and reports on progress regarding such targets where 195
293293 appropriate. 196
294294 (11) Beginning July 1, 2024, each allocation agreement 197
295295 issued by the department relating to cancer center payments 198
296296 under subsection (2) must include all of the following: 199
297297 (a) A line-item budget narrative documenting the annual 200
298298
299299 HB 7087 2024
300300
301301
302302
303303 CODING: Words stricken are deletions; words underlined are additions.
304304 hb7087-00
305305 Page 9 of 9
306306 F L O R I D A H O U S E O F R E P R E S E N T A T I V E S
307307
308308
309309
310310 allocation of funds to a cancer center. 201
311311 (b) A cap on the annual award of 15 percent for 202
312312 administrative expenses. 203
313313 (c) A requirement for the cancer center to submit 204
314314 quarterly reports of all expenditures made by the cancer center 205
315315 with funds received through the Casey DeSantis Cancer Research 206
316316 Program. 207
317317 (d) A provision to allow the department and other state 208
318318 auditing bodies to audit all financial records, supporting 209
319319 documents, statistical records, and any other documents 210
320320 pertinent to the allocation agreement. 211
321321 (e) A provision requiring the annual reporting of outcome 212
322322 data and protocols used in achieving those outcomes. 213
323323 (12)(9) This section is subject to annual appropriation by 214
324324 the Legislature. 215
325325 (13)(10) The department may adopt rules to administer this 216
326326 section. 217
327327 Section 2. This act sha ll take effect July 1, 2024. 218